Skip to main content
Research

Publications: Dr Banu Rudran

Abani O, Abbas A, Abbas F, Abbas J, Abbas K, Abbas M, Abbasi S, Abbass H et al. ( 2023 ) . Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial . The Lancet Diabetes & Endocrinology vol. 11 , ( 12 ) 905 - 914 .
Abani O, Abbas A, Abbas F, Abbas J, Abbas K, Abbas M, Abbasi S, Abbass H et al. ( 2023 ) . Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial . The Lancet vol. 401 , ( 10387 ) 1499 - 1507 .
Abani O, Abbas A, Abbas F, Abbas J, Abbas K, Abbas M, Abbasi S, Abbass H et al. ( 2022 ) . Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis . The Lancet vol. 400 , ( 10349 ) 359 - 368 .
Abani O, Abbas A, Abbas F, Abbas M, Abbasi S, Abbass H, Abbott A, Abdallah N et al. ( 2022 ) . Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial . The Lancet vol. 399 , ( 10325 ) 665 - 676 .
Abani O, Abbas A, Abbas F, Abbas M, Abbasi S, Abbass H, Abbott A, Abdallah N et al. ( 2021 ) . Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial . The Lancet vol. 399 , ( 10320 ) 143 - 151 .
Carugati M, Aliberti S, Sotgiu G, Blasi F, Gori A, Menendez R, Encheva M, Gallego M et al. ( 2021 ) . Correction to: Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study . European Journal of Clinical Microbiology & Infectious Diseases vol. 40 , ( 9 ) 2051 - 2051 .
Arabi YM, Gordon AC, Derde LPG, Nichol AD, Murthy S, Beidh FA, Annane D, Swaidan LA et al. ( 2021 ) . Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial . Intensive Care Medicine vol. 47 , ( 8 ) 867 - 886 .
Abani O, Abbas A, Abbas F, Abbas M, Abbasi S, Abbass H, Abbott A, Abdallah N et al. ( 2021 ) . Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial . The Lancet vol. 397 , ( 10289 ) 2049 - 2059 .
Abani O, Abbas A, Abbas F, Abbas M, Abbasi S, Abbass H, Abbott A, Abdallah N et al. ( 2021 ) . Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial . The Lancet vol. 397 , ( 10285 ) 1637 - 1645 .
Abaleke E, Abbas M, Abbasi S, Abbott A, Abdelaziz A, Abdelbadiee S, Abdelfattah M, Abdul B et al. ( 2021 ) . Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial . The Lancet vol. 397 , ( 10274 ) 605 - 612 .
Gramegna A, Sotgiu G, Di Pasquale M, Radovanovic D, Terraneo S, Reyes LF, Vendrell E, Neves J et al. ( 2020 ) . Correction to: Atypical pathogens in hospitalized patients with community-acquired pneumonia: a worldwide perspective . BMC Infectious Diseases vol. 20 , ( 1 )
Marin-Corral J, Pascual-Guardia S, Amati F, Aliberti S, Masclans JR, Soni N, Rodriguez A, Sibila O et al. ( 2020 ) . Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia . CHEST Journal vol. 159 , ( 1 ) 58 - 72 .
Carugati M, Aliberti S, Sotgiu G, Blasi F, Gori A, Menendez R, Encheva M, Gallego M et al. ( 2020 ) . Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study . European Journal of Clinical Microbiology & Infectious Diseases vol. 39 , ( 8 ) 1513 - 1525 .
Logishetty K, Gofton WT, Rudran B, Beaulé PE, Cobb JP ( 2020 ) . Fully Immersive Virtual Reality for Total Hip Arthroplasty: Objective Measurement of Skills and Transfer of Visuospatial Performance After a Competency-Based Simulation Curriculum . Journal of Bone and Joint Surgery vol. 102 , ( 6 )
Villafuerte D, Aliberti S, Soni NJ, Faverio P, Marcos PJ, Wunderink RG, Rodriguez A, Sibila O et al. ( 2019 ) . Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with community‐acquired pneumonia . Respirology vol. 25 , ( 5 ) 543 - 551 .
Aliberti S, Cook GS, Babu BL, Reyes LF, Rodriguez AH, Sanz F, Soni NJ, Anzueto A et al. ( 2019 ) . International prevalence and risk factors evaluation for drug-resistant Streptococcus pneumoniae pneumonia . Journal of Infection vol. 79 , ( 4 ) 300 - 311 .
Radovanovic D, Sotgiu G, Jankovic M, Mahesh PA, Marcos PJ, Abdalla MI, Di Pasquale MF, Gramegna A et al. ( 2018 ) . An international perspective on hospitalized patients with viral community-acquired pneumonia . European Journal of Internal Medicine vol. 60 , 54 - 70 .
Carugati M, Aliberti S, Reyes LF, Sadud RF, Irfan M, Prat C, Soni NJ, Faverio P et al. ( 2018 ) . Microbiological testing of adults hospitalised with community-acquired pneumonia: an international study . ERJ Open Research vol. 4 , ( 4 ) 00096 - 02018 .
Rudran B, Reader C, Foster J, Hodivala-Dilke K, Sosabowski J, Marshall J ( 2018 ) . P1.03-19 Antibody Blockade of Integrin Alpha-V-Beta-6 (avb6) as a Novel Treatment for NSCLC . Journal of Thoracic Oncology . vol. 13 , s518 - s519 .
Di Pasquale MF, Sotgiu G, Gramegna A, Radovanovic D, Terraneo S, Reyes LF, Rupp J, del Castillo JG et al. ( 2018 ) . Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients . Clinical Infectious Diseases vol. 68 , ( 9 ) 1482 - 1493 .
Restrepo MI, Babu BL, Reyes LF, Chalmers JD, Soni NJ, Sibila O, Faverio P, Cilloniz C et al. ( 2018 ) . Burden and Risk Factors for Pseudomonas aeruginosa Community-acquired Pneumonia: a Multinational Point Prevalence Study of Hospitalised Patients . European Respiratory Journal1701190 - 1701190 .
Rudran B, Reader C, Foster J, Hodivala-Dilke K, Sosabowski J, Marshall J ( 2018 ) . 12 Blockade of integrin alpha-v-beta-6 (αvβ6) reduces the invasive potential of NSCLC . Lung Cancer vol. 115 , s5 - s6 .
Rudran B, Reader C, Foster J, Hodivala-Dilke K, Sosabowski J, Marshall J ( 2018 ) . Blockade of integrin alpha-v-beta-6 (αvβ6) reduces the invasive potential of NSCLC . LUNG CANCER . vol. 115 , S5 - S6 .
Rudran B, Desai A, Luzarraga M, Hodivala-Dilke K, Foster J, Sosabowski J, Marshall J ( 2017 ) . Development of non-invasive imaging of integrin alpha-v-beta-6 (alpha v beta 6)-positive lung cancers in advance of testing alpha v beta 6-targeted therapies . Lung Cancer . Conference: British Thoracic Oncology Group Conference 2017 ( Dublin, Ireland ) from: 25/01/2017 to: 27/01/2017 , vol. 103 , S4 - S4 .
Rudran B, Desai A, Luzarraga M, Hodivala-Dilke K, Foster J, Sosabowski J, Marshall J ( 2017 ) . 6: Development of non-invasive imaging of integrin alpha-v-beta-6 (αvβ6)-positive lung cancers in advance of testing αvβ6-targeted therapies . Lung Cancer vol. 103 ,
Aliberti S, Reyes LF, Faverio P, Sotgiu G, Dore S, Rodriguez AH, Soni NJ, Restrepo MI et al. ( 2016 ) . Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study . The Lancet Infectious Diseases vol. 16 , ( 12 ) 1364 - 1376 .
Rudran B, Marshall JF ( 2015 ) . 7: The integrin αvβ6: a new target for therapy in non-small cell lung cancer . Lung Cancer . vol. 87 ,
Rudran B, Idris L, Childs C, Riccio F, Loganathan S, Shaw TJ ( 2011 ) . P214 Acute exacerbations of COPD: a review of resuscitation status and associations with prognostic factors in hospital admissions . Thorax . vol. 66 , a154 - a155 .
Shafiq I, Huggett K, Rudran B, Morrison G, Idris L, Shaw T ( 2011 ) . Use Of COPD Assessment Test (CAT) To Monitor Recovery From An Acute Exacerbation . Conference: C44. COPD: NOVEL DIAGNOSTIC TOOLSa4603 - a4603 .
Rudran B, Jarvis M, Thomas D, Sanmani L, Ranaweera N, Cook A, George S, Cummin A et al. ( 2011 ) . HIV testing in acute medical admissions . HIV MEDICINE . vol. 12 , 62 - 62 .